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BY-NC-ND license (http://creativecomAbstract Somatic rearranged during transfection (RET ) mutations are reported in 40e50% of
sporadic medullary thyroid carcinoma (sMTC) patients with prognostic significance. As there is
a lack of somatic RET mutations reported previously for the Taiwanese population, we tried to
assess the presence of somatic RET mutations and evaluate the potential outcome predictors
for our sMTC patients. We collected data from seven sMTC patients from the years 1997 to 2005
and analyzed their clinic-pathological features up to 2015. All patients were still alive to follow
up for 11w18 years. Tumor DNAs were extracted to assess exons 10e11 and 13e16, and the
intron-exon boundaries of the RET gene. Six cases (86%) were screened positive of somatic
RET gene mutations in hotspot regions, one at M918T, one at C620R, and three at C634S, with
another two rare mutations at L629Q and V642I. Comparing the current tumor, node, metas-
tases staging system, the 10-year survival outcomes for our sMTC patients was not predicted
by serum calcitonin and/or carcinoembryonic antigen, surgical extent, and presence of the so-
matic RET gene mutations. The small cohort demonstrated a relatively good outcome of sMTCeclare no conflicts of interest.
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546 L.-L. Chuang et al.patients to survive >10 years. In addition, intensive treatment with total thyroidectomy with
extensive neck lymph node dissection seemed to be the critical determinant of better survival
outcome for sMTC patients.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Medullary thyroid carcinoma (MTC), arising from calcitonin-
secreting parafollicular C cells, accounts for 1e2% of all
thyroid cancers. Sporadic MTC accounts for the majority
(75%), while the remaining hereditary MTC is caused by
germline mutations composed of multiple endocrine
neoplasia (MEN) Type 2A, Type 2B, and familial MTC [1e3].
The rearranged during transfection (RET ) proto-oncogene
mutation has been identified as the driver for the onset and
progression of hereditary MTC. The RET proto-oncogene is
composed of 21 exons located on chromosome 10q11-2 and
encodes a tyrosine kinase transmembrane receptor. The re-
ceptor has three domains: (1) extracellular domain (exon
1e10) with a distal cadherin like region and a juxta-
membrane cysteine-rich region; (2) transmembrane
domain (exon 10e11); and (3) intracellular domain (exon
12e21) with tyrosine kinase activity. Previous studies have
demonstrated that RET oncogene mutation results in
constitutively mutant ret proteins, while activation of the
ret protein induces autophosphorylation of tyrosine kinase.
The continuous activation signaling could lead to unregu-
lated cell proliferation and malignant transformations [4,5].
Germline RET oncogene mutations were found in almost
all hereditary MTC patients. Sporadic MTC (sMTC) is diag-
nosed and defined by a lack of RET gene germline mutation,
no family history of MTCs, and negative clinical and labo-
ratory evidence of other endocrine neoplasms. Somatic RET
mutations are reported to occur in 40e50% of sMTC tumors
with various prevalence in different ethnic populations.
“Hot spot” regions of somatic RET mutation were mostly
found in exon 10, exon 11, and exon 16 [6e9]. Harboring
somatic RET mutations in sMTC has been reported to signify
larger tumor size, more aggressiveness, poor prognosis, and
good drug response in several studies [10e12]. However,
the clinical behavior of sMTC is still unpredictable by the
current staging system [3,10].
Previously, Chang et al. [13] did not report any RET
mutation in hot spot regions in sMTC cases in a Taiwanese
population. Our study surveyed potential common somatic
RET mutations in our sMTC cases. We also compared the
long-term outcomes and explored the prognostic signifi-
cance of these RET mutations among Taiwanese patients.Methods
We collected data from seven patients (1 male, 6 females)
diagnosed with sMTC at Kaohsiung Medical University Hos-
pital within 8 years (1997e2005). All of these patients werediagnosed at the age of 49.3  16.9 years (from 19 years to
76 years). Their initial manifestations were nearly all
palpable neck lumps. Surgical intervention with ipsilateral
or bilateral thyroidectomy was done initially, com-
plemented by lymph node dissection (Table 1). These pa-
tients were still alive and followed in our outpatient clinic
for 11e18 years up to the end of this study in 2015. They
were followed in an outpatient clinic to evaluate the clinical
status via scheduled thyroid ultrasound, neck computerized
tomography (CT), thallium201 thyroid or whole body scan,
Technetium (99mTc) sestamibi (Tc99m-MIBI) combined with
single photon emission computed tomography (SPECT/CT)
scan in addition to the periodic evaluation of serum calci-
tonin or carcinoembryonic antigen (CEA) by radioimmuno-
assay (Cisbio Bioassays, Codolet, France). Fludeoxyglucose18
positron emission tomography scans were also used to help
define free of tumor recurrence or metastasis.
Under the approval and supervision of the Institutional
Review Board of Kaohsiung Medical University Hospital (IRB
KMUH-98-00237), we started the study after obtaining
informed consent from all patients. DNA was extracted
from blood and formalin fixed paraffin embedded (FFPE)
block by the QuickExtract FFPE DNA extraction kit (Epi-
centre, Madison, WI, USA) according to the manufacturer’s
protocol. Exons 10e11, 13e16, and the intron-exon
boundaries of the RET gene were amplified by semi-
nested polymerase chain reaction (PCR) to increase the
sensitivity for the suboptimal DNA quality from blood and
FFPE samples. Briefly, first PCR was performed with FFPE
DNA plus outer forward, reverse (R) primers, and PCR
master mixture. A 10-fold dilution of the first PCR products
was used as the template for a second PCR with inner for-
ward and R primers. PCR products were confirmed by
electrophoresis in 1.5% agarose gel and sequenced by an
ABI 3730XL DNA analyzer (Applied Biosystems, Foster City,
CA, USA). PCR amplification primers are listed in Table 2.
The reference sequences of the RET gene and mRNA were
NG_007489.1 and NM_020975.4.
This study was approved by IRB KMUH-98-00237and was
conducted in accordance with the ethical standards of
Institutional Review Board (IRB) Committee of Kaohsiung
Medical University Hospital (KMUH).
Results
Within the period of 1997e2005, the incidence of newly-
diagnosed thyroid carcinoma in our hospital was around
72e90 patients/year. The incidence of MTC accounts for
about 1% of all thyroid carcinoma in our hospital. All of
these seven cases were still alive until 2015 with different
Table 1 Outcome with RET proto-oncogene mutations in case series of sporadic medullary thyroid carcinoma.
Case Age (y) Sex TNM stagea Pathology Initial treatment Tumor markers
(pre op)
Tumor marker (post op) Mutation Follow (y) Outcome and treatment
1 76 F T4aN0M0
Stage IVA
5 cm with
extrathyroid invasion
Total thyroidectomy CEA 1.9 ng/mL V642I
L629Q
18 Alive, no recurrence
2 46 M T2N1bM0
Stage IVA
2.6 cm with lymph
node metastasis
Total thyroidectomy þ
LN dissection
CEA 41.4 ng/mLb
CEA 3.89 ng/mL and
Ct 44 pg/mL (2 y);
CEA 37.6 ng/mL and
Ct 665.9 pg/mL (8 y)
CEA 16.1 ng/mL (9 y)
CEA 26.74 ng/mL (10 y)
M918T 13 Alive,
1st LN dissection (8 y);
2nd LN dissection (10 y)
3 53 F T3N0M0
Stage II
2 cm with capsular
invasion
Total thyroidectomy þ
LN dissection
Ct 111 pg/mL,c
CEA 90.1 ng/mL
Ct 1.0 pg/mL and
CEA 1.16 ng/mLb
C634S 11 Alive, no recurrence
4 49 F T3N0M0
Stage II
3.2 cm with vascular,
capsular and
extrathyroid invasion
Left lobectomy Ct 513.54 pg/mL and
CEA 23.92 ng/mL (6 y)
Ct 703.71 pg/mL (7 y)
Ct 809.69 pg/mL (8 y)
C620R 11 Alive,
1st LN dissection (5 y);
2nd total thyroidectomy þ
LN dissection (8);
no more recurrence
5 46 F T2N0M0
Stage II
3.5 cm, encapsulated Right lobectomy Ct 1.0 pg/mL and
CEA 1.15 ng/mLb;
Ct 18.8 pg/mL (1 y)
none 11 Alive,
total thyroidectomy þ
LN dissection (3 y); then
no recurrence
6 56 F T2N0M0
Stage II
2 cm Total thyroidectomy Ct 61.9 pg/mL (3 y)
Ct 31 pg/mL (4 y)
CEA 0.7 ng/mL (5 y)
C634S
L629Q
16 Alive, no recurrence
7 19 F T2N0M0
Stage II
2.5 cm with vascular
invasion
Total thyroidectomy CEA 10.9 ng/mLb
CEA 1.24 ng/mL (1 y)
C634S 14 Alive, no recurrence
CEA Z carcinoembryonic antigen; Ct Z calcitonin; LN Z lymph nodes; TNM Z tumor, node, metastases.
a Staging of medullary thyroid carcinoma according to American Joint Cancer Committee 7th edition.
b Serum calcitonin and CEA were assessed at the initial follow up within 3 months after operation.
c Serum Ct < 10 pg/mL and CEA < 5 ng/dL were referenced as normal.
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Table 2 Primers used for semi-nested polymerase chain reaction amplification of human RET gene.
Primer Sequences Length (bp)
10_OF/IF
10_R
ACACTGCCCTGGAAATATGG/TATGGGCGCCTGGGGT
CTCAGATGTGCTGTTGAGAC
263/248
11_OF/IF
11_R
CCTGGAAGGCAGCTGGG/TTGTGGGCAAACTTGTGGTA
CAGAGCATACGCAGCCTGTA
388/193
13_OF/IF
13_R
TGACCTGGTATGGTCATGGA/GAAGGGGCTTCCAGGAGC
CTGGGTGCAGTGGCTGC
221/203
14_OF/IF
14_R
AAGACCCAAGCTGCCTGAC/AGGGCCCCCTCTCTCCGC
GCTGGGTGCAGAGCCATAT
295/266
15_OF/IF
15_R
AGTGACCGCTGCTGCCTGG/ATGGCCTGACGACTCGTGCT
TTCCCAAGGGCACTGCCTGC
253/232
16_OF/IF
16_R
TGGCCAAGCTGCACAGACGG/TGTAACCTCCACCCCAAGAG
TCTCCTTTACCCCTCCTTCC
231/176
bp Z base pair; IF Z inner forward primer; OF Z outer forward primer; R Z reverse primer.
Figure 1. Chromatogram of RET mutations in sporadic
medullary carcinoma. Sanger sequence traces of the patients
with RET gene mutation were performed by ABI 3730XL DNA
Analyzer. These RET gene mutations included M918T (A); V642I
variant (B); C634S (C); C620R (D); and L629Q and C634S mu-
tations (E). * indicates homozygous mutation.
548 L.-L. Chuang et al.clinical courses. As shown in Table 1, all patients survived
10 years or more, even though one was diagnosed initially
with Stage IVA at 76 years old. The extrathyroid extension
of MTC, which occurred in Case 1 and Case 4, was docu-
mented by initial pathologic report. The cancer work-up of
thallium201 whole body scan was performed for Case 1 and
Case 5, Tc99m-MIBI combined with SPECT/CT scan for Case
2, Case 3, Case 4, and Case 7, neck CT scan for Case 4, and
positron emission tomography scan for Case 3 and Case 4
within the follow-up period. There was no evidence of
distant metastases detected by the above routine cancer
work-up. As substantial difficulty existed for cytodiagnosis
of medullary carcinoma, the preoperation calcitonin or CEA
tumor marker was measured only in Case 1 and Case 2. The
periodic biochemical analysis of CEA and calcitonin is
shown in the supplementary figure.
Comparing index Case 2, Case 4, and Case 5 with tumor
recurrence and Case 1, Case 3, Case 6, and Case 7 without
tumor recurrence, it appeared that initially positive lymph
node metastasis and limited surgical exploration contrib-
uted to tumor recurrence but was not related to tumor size
or extrathyroid extension. Lymph node metastasis signified
a risk for local recurrence in lymph nodes even after total
thyroidectomy and lymph node dissection. However, total
thyroidectomy might reduce recurrence even with the
initial presence of capsular invasion or extrathyroid inva-
sion. Absence of tumor recurrence in Case 1, Case 3, Case
6, and Case 7 was compatible with normal CEA during
follow-up. Continuously elevated calcitonin or CEA was
significantly correlated to the presence of tumor recur-
rence with lymph node metastasis.
There were eight somatic RET gene mutations found in
our seven patients (Figure 1). The prevalence of RET gene
mutation was near 86% in our population. There were three
mutations at the hot spot codon p.C634S (TGC > AGC,
TGC > AGC, TGC > TCC) in exon 11. Case 4 was screened
with p.C620R (TGC > CGC, homozygous) in exon 10 and
Case 2 had a mutation at M918T (ATG > ACG) in exon 16.
Patients with somatic mutation at p.C634S did not have
recurrence during more than 10 years of follow-up. How-
ever, cases with somatic mutations of p.M918T or p.C620R
experienced much worse outcomes in terms of frequentrecurrence (Table 1). There were novel mutations screened
at p.L629Q (CTG > CAG) in exon 11 in Case 1 and Case 6.
Case 1 also had a novel gene mutation at p.V642I
(GTC > ATC, homozygous) in exon 11 (Table 1). Referring to
the novel variants at p.L629Q and p.V642I in exon 11, we
made “in silico” analysis by PolyPhen-2 and Mutation
Taster. The p.L629Q was predicted as “possibly damaging”
with a score of 0.668 by PolyPhen-2 and polymorphism with
a score of 113 by Mutation Taster. As for p.V642I, the
Somatic RET mutations in sporadic MTC 549PolyPhen-2 predicted it as “benign” with a score of 0.012
and Mutation Taster predicted it as polymorphism with a
score of 29.Discussion
The tumor, node, metastases (TNM) classification system of
the 6th edition of American Joint Committee on Cancer
(AJCC) revealed 10-year MTC survival rates for Stage I,
Stage II, Stage III, and Stage IV as 100%, 93%, 71%, and 21%,
respectively [14]. Overall the reported 10-year disease-
specific survival varies from 50% to 96.6% in different se-
ries. So far, there is no reliable and concordant prognostic
model to predict the risk of relapse and death [2]. The
TNM/AJCC staging system could provide adequate risk
stratification for disease-specific mortality, but is unable to
predict disease persistence, biochemical persistence, or
recurrence at long-term surveillance [2,15,16]. Based on
the multivariate analysis achieved by the population-based
Surveillance, Epidemiology and End Results registry in
America, the advanced age at diagnosis, size of primary
tumor, range of surgical exploration, lymph nodes, or
distant metastases appear to determine the prognosis.
However, only age and stage remained significantly to be
independent predictors for prognosis on multivariate anal-
ysis [14]. Age at diagnosis is an independent predictor of
survival, with an increment of 5.2% risk of death for each
additional year of age. Stage of distant metastasis had the
highest hazard ratio at 4.47, while regional stage (extension
beyond the thyroid directly into the surrounding tissues or
lymph nodes) had a hazard ratio of 2.69 for decreased
survival than localized tumor confined to the thyroid. Total
thyroidectomy with lymph node dissection versus lesser
resection (lobectomy, subtotal thyroidectomy absent, or
limited lymph node dissection) also independently pre-
dicted a better outcome [14].
Reviewing our case series, there were no distant me-
tastases and the 10 year disease-specific survival rate
seemed better than the Surveillance, Epidemiology and
End Results database. The prognosis predicted by age or
advanced pathologic staging by the current TNM/AJCC
system could not sufficiently determine the outcome of
our cases series because of neglecting the impact of serum
tumor marker (calcitonin and/or CEA) and lymph node
metastasis [3]. Our case series has demonstrated that
continuous elevation of the calcitonin or CEA was signifi-
cantly correlated to the presence of tumor recurrence
with lymph node metastasis. However, the stepwise sur-
gical interventions achieving final total thyroidectomy and
radical lymph node dissection for each case may
contribute to the relatively good prognosis for our
patients.
Because MTC has been reported with a high rate
(50e75%) of lymph node metastases and substantial inci-
dence of multifocal tumors (0e22%), postoperative evalu-
ation and treatment turns out to be critical for the outcome
[17e19]. Neck ultrasound and other imaging studies (neck
or chest CT scan, bone scan) are considered to evaluate the
residual or metastatic tumor burden if the detectable
calcitonin is still >150 pg/mL. Then, additional therapies,
e.g., bilateral total thyroidectomy with central and/orlocalized lymph node dissection or external beam irradia-
tion therapy should be offered to treat persistent, pro-
gressive or symptomatic locoregional tumor burden
identified as more than 1 cm [12,20,21].
According to the recommendations in the American
Thyroid Association guidelines, concurrent assessment of
the baseline calcitonin and CEA around 2e3 months after
operation is the critical step to clarify the risk status for
MTC patients [20,21]. Serum calcitonin and CEA were
significantly correlated with tumor burden and disease
progression [21]. Serum calcitonin and CEA were highly
correlated in 80% of MTC patients, while disproportionately
high CEA with limited calcitonin level indicates poor dif-
ferentiation of the MTC. The most aggressive tumors had
persistent and intense CEA staining but minimal calcitonin
staining due to loss of expression during the dedifferenti-
ation process [3,11,20]. As reported by Barbet et al. [22],
doubling time of serum calcitonin (Ct DT) was regarded as
the most sensitive predictor of survival, better than calci-
tonin, CEA, CEA DT, or current TNM staging system. Five and
10-year survival for MTC patients was 25% and 8% if their Ct
DT was <6 months. The 5-year and 10-year survivals
improved to 92% and 37%, respectively, if the Ct DT was
within 6e24 months, while all patients could survive
>10 years if their Ct DT was >2 years [22]. According to
2012 European Thyroid Association guidelines, basal serum
calcitonin higher than the upper limit of the normal range
should be considered as “positive” and the calcitonin cutoff
should also be able to discriminate C-cell hyperplasia or
microMTC from bigger tumors and neck lymph node me-
tastases. MTC tumors bigger than 0.5 cm with lymph node
metastases are never reported to have a basal calcitonin
level <30e60 pg/mL [17]. However, our case series
revealed different clinical courses compared with previous
conclusions. For Case 1, the preoperative CEA was low and
even exhibited a huge tumor burden (5 cm with extra-
thyroid invasion). The raised calcitonin or CEA in Case 2,
Case 4, and Case 5 was compatible with lymph node me-
tastases during postoperative follow-up. Serum CEA or
calcitonin in Case 6 and Case 7 declined gradually at 5 years
and 1 year after operation without any evidence of recur-
rence during follow-up beyond 10 years. Case 5 had a rapid
Ct DT from 1.0 pg/mL up to 18.8 pg/mL within 1 year after
lobectomy but is still alive with no recurrence beyond
11 years, even though complete total thyroidectomy and
lymph node dissection was delayed for 2 years. From our
limited case observations, we found that undetectable
serum calcitonin or CEA after operation could not predict
recurrence well. Also, initially detectable calcitonin or CEA
just postoperation or within 3 months did not indicate
tumor persistence. This is compatible with previous clinical
investigation that postoperative 3 months is the optimal
time to determine the nadir of serum calcitonin, but serum
CEA may take even longer to reach a nadir [3,12]. Thus we
suggested periodical follow-up of the tumor markers is
necessary to compare serial alterations and verify
biochemical remission or recurrence. In addition, serum
calcitonin or CEA is used as a reference to judge tumor
persistence or recurrence rather than as a predictor of
survival.
The genotype of hereditary MTC is recognized to highly
correlate with the phenotype [9,16]. According to the
550 L.-L. Chuang et al.American Thyroid Association guidelines, germline RET
mutation at codon 918 (ATG to ACG, p.M918T) in exon 16 is
associated with the “highest” risk status (level D) at
younger onset, with the highest risk of metastases and
disease-specific mortality. Hereditary MTC with germline
RET mutation at codon 634, encoding a cysteine-rich
extracellular domain, was classified as “high” risk level C,
with higher transforming activity and tumor aggressiveness
compared with the other codons (609, 611, 618, 620, and
630) [3,17]. Existence of somatic RET mutations in sMTC
was also found to correlate with higher mitotic cancer cell
activity [6,9]. Prevalence of the somatic RET mutation
harbored in sMTC varies from 40% to 65% in different series.
Somatic RET mutation was demonstrated to signify some
clinicopathologic features [6,7,9,11]. p.M918T somatic
mutation was the most common mutation in sMTC and
significantly contributed to a poor prognosis with larger
tumors and higher lymph node and distant metastasis rates,
frequent multifocal tumors, more advanced stage at diag-
nosis, more persistent disease after operation, more
relapse, and worse outcomes [6,9,17]. In our case series
only one patient (Case 2, 14%) harbored the M918T muta-
tion, which was clinically compatible with recurrent lymph
node metastases even after initial wide total thyroidec-
tomy and lymph node dissection followed by two more
lymph node dissections. Our index Case 4 harboring a so-
matic p.C620R mutation presented initially with extra-
thyroid extension, treated by left lobectomy, and
experienced recurrent lymph node metastases. Total thy-
roidectomy and radical lymph node dissection was done
8 years later, and the outcome was still good with no tumor
recurrence at the study end. All three cases (43%) having a
C634S mutation had good prognosis and no recurrence
beyond 10 years. Since they all were treated with bilateral
total thyroidectomy at first, the clinical significance of the
C634S mutation is hard to assess by our limited case
experience.
Limitations of this study included small MTC cases in our
thyroid cancer population. The diagnosis of sporadic MTC
by clinicians was only based on the absence of family his-
tory or any associated endocrine tumor emerged among
three generations within 10 years of follow up. Peripheral
blood samples were not drawn to detect germline muta-
tions at the time of data collection. Functional study was
not elucidated in the pathogenesis of sMTC for the two
novel variants found in this study.
Our study evidenced a relatively high frequency (86%) of
the somatic RET gene mutation in sMTC. We found no
obvious correlation between the somatic RET mutations
and 10-year survival outcome in cases of sMTCs. However,
sMTC patients carrying the M918T mutation may have
greater risk of lymph node metastases and may need more
aggressive surgical intervention during follow-up. Intensive
treatment with total thyroidectomy and repeated neck
lymph node dissection seemed to be the critical determi-
nant to achieve better survival outcome for sMTC patients.
However, a randomized control study should be pro-
grammed with more patients recruited for a definite
conclusion. From our results, we agreed with the guideline
that there is still no strong evidence or indication for
routine screening of the somatic RET mutation to deter-
mine treatment strategies for sMTC patients.Acknowledgments
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